A Study of DTC in Patients With AIDS and AIDS Related Complex

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

Key facts

Study ID

NCT00002069

Run by

Merieux Institute

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Zidovudine (AZT).

You may not qualify if…

• Co-existing Condition:
• Patients with the following are excluded:
• Active opportunistic infection or progressive Kaposi's sarcoma (KS).
• Dementia.
• Lymphoma.
• Concurrent Medication:
• Excluded within 3 weeks of study entry:
• Other experimental AIDS therapy.
• Patients with the following are excluded:
• Active opportunistic infection or progressive Kaposi's sarcoma (KS).
• Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

Where it is running

• Univ of Arizona / Arizona Cancer Ctr — Tucson, Arizona, United States
• USC School of Medicine / Norris Cancer Hosp — Los Angeles, California, United States
• San Francisco AIDS Clinic / San Francisco Gen Hosp — San Francisco, California, United States
• Portion Med Group — Sherman Oaks, California, United States
• Florida Keys Memorial Hosp — Key West, Florida, United States
• SUNY / Health Sciences Ctr at Brooklyn — Brooklyn, New York, United States
• Duke Univ Med Ctr — Durham, North Carolina, United States
• Dr Gary Brewton — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.